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Background: Antidepressants are among the most commonly prescribed drugs in primary care in England and
their use is increasing. This is largely due to longer durations of treatment of depression. Observational studies have
shown some differences in adverse outcomes associated with different antidepressant drugs but relatively little is
known about their relative safety particularly with long term use. The primary aim of this study is to determine the
relative and absolute risks of pre-defined adverse events comparing different classes of antidepressant drugs in
adults aged under 65 years and diagnosed with depression.
Methods/design: The study will identify a cohort of patients with a first recorded diagnosis of depression between
1/1/2000 and 31/07/2011, and made between the ages of 20 to 64 years using a large primary care database
(QResearch). Patients will be followed up until 1/08/2012. Details of all prescriptions for antidepressants in patients
in the cohort will be extracted, including the date of each prescription, the type of antidepressant drug, the dose
and total quantity prescribed. Prospectively recorded data will be used to ascertain information on adverse
outcomes that occurred during follow-up and after entry into the cohort. These are: all-cause mortality, suicide,
attempted suicide/self-harm, sudden death, antidepressant overdose/poisoning, myocardial infarction, stroke/
transient ischaemic attack, cardiac arrhythmia, epilepsy/seizures, upper gastrointestinal bleeding, falls, fractures,
adverse drug reactions and motor vehicle crashes. Cox proportional hazard models will be used to estimate the
association of the outcomes with class of antidepressant drug adjusting for potential confounding variables. The
analyses will also examine associations by duration and dose and with the most frequently prescribed individual
antidepressant drugs. Self-controlled case series analyses will be used to estimate the relative incidence of the
outcomes of interest for defined time periods of antidepressant use.
Discussion: The results of this study will help to establish the relative safety and balance of risks for different
antidepressant drugs in people aged under 65.
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Antidepressant drugs are among the most commonly
prescribed drugs in primary care; more than 46 million
prescriptions for antidepressants were issued in England in
2011, an increase of 48% compared with 2006 [1]. The
majority of antidepressant prescriptions in 2012 (54%) were
for selective serotonin reuptake inhibitors (SSRIs) with 29%
for tricyclic antidepressants (TCAs) and 17% for other* Correspondence: carol.coupland@nottingham.ac.uk
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reproduction in any medium, provided the orantidepressant drugs [2]. Studies have shown that the large
rise in antidepressant volumes is mainly due to longer
durations of treatment [3,4]. A systematic review of
antidepressants compared with placebo in trials
conducted in primary care in patients aged less than
65 found that both TCAs and SSRIs are effective
treatments for depression in primary care [5]. Most trials
of antidepressants are however short term, in selected
populations and comparatively little is known about their
relative safety particularly with long term use.
Some observational studies have shown increased risks
of suicide associated with antidepressant use [6-8], withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evidence to support any differences between classes of
antidepressant. Other adverse effects associated with
antidepressants in some observational studies include
myocardial infarction [9,10], stroke [11-14], fracture
[15,16], and gastrointestinal bleeding [17], but findings
have been inconsistent, many studies have been small
and short-term, some studies have only studied one class of
antidepressants, and few studies have looked at individual
drugs or dose, so the evidence on antidepressant safety is
far from conclusive.
A study we carried out to investigate safety and harms
of antidepressant drugs in older people aged 65 years
and over [13,18] found that selective serotonin reuptake
inhibitors and drugs in the group of other antidepressants
were associated with an increased risk of several adverse
outcomes compared with tricyclic antidepressants. The
current study in adults aged less than 65 years will compare
results in younger people so that a comprehensive assess-
ment can be made of antidepressant safety across adults of
all ages. The primary study objective is to determine the
relative and absolute risks of pre-defined adverse events in
adults aged under 65 and diagnosed with depression
comparing the different classes of antidepressant drugs.
Methods/design
The study will use a large primary care database
(QResearch, version 34) to identify an open cohort of
patients with a first recorded diagnosis of depression
between 1/1/2000 and 31/07/2011, and made between
the ages of 20 to 64. QResearch is a large consolidated
database derived from the anonymised health records of
over 12 million patients. The data currently come from
more than 600 general practices across the UK using the
EMIS clinical computer system.
Eligibility criteria
Diagnostic Read codes will be used to identify an open
cohort of patients with a diagnosis of depression, using
case definitions that have been used in previous studies
[7,9,18]. Patients will be eligible for inclusion in the
study cohort if they have a first recorded diagnosis of
depression, made between the ages of 20 and 64 and
between 1/1/2000 and 31/07/2011. Patients will only be
eligible for inclusion if their diagnosis occurred at least
12 months after registration with a study practice and
after the date of the installation of the practice EMIS
computer system The cohort of eligible patients will
include patients with a diagnosis of depression who were
treated with antidepressant medication and also patients
with a diagnosis of depression who did not receive
antidepressant treatment. To reduce the risk of indication
and channeling bias patients who received prescriptions
for antidepressants but did not have a recorded diagnosisof depression will not be eligible for inclusion as the
prescriptions may have been for conditions other than
depression, such as neuropathic pain or eating disorders.
Exclusion criteria
Patients will be excluded from the cohort if they: were tem-
porary residents; had a diagnosis of schizophrenia, bipolar
disorder or other types of psychoses or had been prescribed
lithium or antimanic drugs at the study entry date; had a
previous recorded diagnosis of depression; or had received
prescriptions for an antidepressant either before the study
start date (1/1/2000), before their date of registration with
the practice (if later), before the age of 20 or more than 36
months before their recorded diagnosis of depression.
Duration of follow up
Since some patients may have received an antidepressant
for treatment of depression before the diagnosis of depres-
sion was recorded, the index date which marks the date of
entry into the study cohort for analysis will be defined as
the date of the first recorded diagnosis of depression, or the
date of the first prescription for an antidepressant if that
occurred before the recorded date of depression.
Participants will be followed-up in the database from
their index date until the earliest of: date of death,
date of leaving the practice, or the end of the follow-up
period (1/08/2012).
Exposures
The exposure of interest is antidepressant medication. We
will extract details of all prescriptions for antidepressants in
patients in the study cohort, following their initial diagnosis
of depression (or first prescription for an antidepressant if
no more than 36 months before their recorded diagnosis of
depression), up to the study end date (1/08/2012), or the
date of death or leaving the practice if this occurs earlier.
Extracted information will include the date of each
prescription, the type of antidepressant drug, the dose
and total quantity prescribed.
The antidepressant drugs will be grouped for analysis
according to the major classes as described in the British
National Formulary (BNF), namely:
 tricyclic and related antidepressants (TCAs -
section 4.3.1),
 selective serotonin reuptake inhibitors (SSRIs -
section 4.3.3),
 monoamine oxidase inhibitors (MAOIs - section 4.3.2)
 other antidepressants (Others - section 4.3.4).
Some patients may receive prescriptions for different
drugs within a class or drugs from different classes on
the same date. These prescriptions will be identified and
classified as combined prescriptions for some analyses.
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and dose of the antidepressant drugs will be examined
in the analyses. We will determine the duration of each
prescription in days by dividing the number of tablets
prescribed by the dosing directions (e.g. number of tablets
to be taken per day). Where the number of tablets
prescribed is recorded but the dosing directions are
missing or not sufficiently detailed we will use an assumed
duration based on the median duration of prescriptions
for those prescriptions where dosing directions were
available, taking account of the number of tablets
prescribed as in our previous study [18].
We will calculate the daily dose of each prescription
by multiplying the specified dose of each tablet prescribed
by the number of tablets to be taken each day. To enable
comparison of doses between the antidepressant classes,
we will convert the dose per day for each prescribed drug
to a defined daily dose (DDD), defined as the assumed
average maintenance dose per day for a drug used for its
main indication in adults, using the DDD values assigned
by the World Health Organisation’s Collaborating
Centre for Drug Statistics Methodology (www.whocc.
no/atc_ddd_index).
Individual antidepressant drugs will also be assessed
where numbers are sufficient. In our previous study we
examined the top 11 most commonly prescribed individual
antidepressant drugs separately in the analyses of the more
common outcomes [18].
Outcomes
We have identified a number of potential adverse effects
of antidepressants from the literature. Information on
these outcomes will be extracted from the primary care
computer records of patients in the cohort and from
linked death certificates for patients who died during the
study period. Outcomes will only be included if they
occurred after the index date of entry into the study cohort.
Computer recorded Read codes and ICD 9 and 10 codes
from linked death certificates where appropriate will be
used to identify patients with each of the outcomes of
interest.
The outcomes that will be assessed are:
 all-cause mortality
 suicide (including open verdicts)
 attempted suicide/self-harm
 sudden death
 overdose/poisoning with an antidepressant
 myocardial infarction
 stroke/transient ischaemic attack (TIA)
 cardiac arrhythmia
 epilepsy/seizures
 upper gastrointestinal bleeding
 falls fractures
 adverse drug reactions (including bullous eruption)
 motor vehicle crash.
The date of occurrence of the outcome used in
analysis will be the first recorded date of the outcome
during follow-up.
Confounding variables
Information will also be extracted on potential confounding
variables including:
 age at index date
 sex
 year of diagnosis of depression
 severity of index diagnosis of depression (categorised
as mild, moderate or severe based on the Read code
for the index diagnosis, using codes published by
Martinez and colleagues [7] and some additional
classification by a member of the study team (RM))
 deprivation, based on Townsend deprivation score
for the patients postcode in quintiles
 smoking status (non-smoker, ex-smoker, current
smoker – light/moderate/heavy)
 alcohol intake (none, trivial <1 unit/day, light 1–2
units/day, medium 3–6 units/day, heavy 7–9 units/
day, very heavy >9 units/day)
 ethnic group (white/not recorded, Indian, Pakistani,
Bangladeshi, other Asian, black African, black
Caribbean, Chinese, other including mixed)
 comorbidities at baseline (coronary heart disease,
diabetes, hypertension, stroke/TIA, cancer, epilepsy/
seizures, hypothyroidism, rheumatoid arthritis,
osteoarthritis, osteoporosis, liver disease, renal
disease, asthma/chronic obstructive airways disease,
obsessive-compulsive disorder) identified using
appropriate Read codes in the patients records
 use of other drugs at baseline (statins, NSAIDS,
anti-psychotics, aspirin, antihypertensive drugs,
anticonvulsants, hypnotics/anxiolytics, oral
contraceptives, HRT, bisphosphonates warfarin and
anticoagulants).
 In addition for the analysis of suicide as an outcome,
previous attempted suicide/self-harm at baseline will
be considered a confounding variable. For the
analysis of fracture, previous falls will be considered
a confounding variable.
Statistical analysis
Descriptive analyses will be carried out to describe baseline
characteristics of patients in the study cohort. We will
describe patterns of antidepressant use according to class
and individual type of antidepressant prescribed, duration
of use and dose, and will examine these patterns by sex, age
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comorbidities and study year.
The primary statistical analysis for the cohort study
will comprise a series of survival analyses to assess the
relationship between exposure to antidepressant drugs
and the adverse outcomes. Cox’s proportion hazards
models will be used to analyse the cohort data to calculate
hazard ratios and 95% confidence intervals, with anti-
depressant exposure treated as a time-varying exposure.
The time varying analysis accounts for patients starting and
stopping treatment during follow-up and also changing
between treatments during follow-up. For example, a
patient diagnosed with depression who received treatment
with an SSRI 3 months after diagnosis and who stopped
treatment 9 months after diagnosis will be analysed in the
“no current treatment” group for time 0 to 3 months, the
“SSRI treatment” group for 3 to 9 months, and the “no
current treatment” group after 9 months
The main statistical analysis will only include adverse
outcomes recorded within the first 5 years after the index
date (because the confounders may change considerably
over a longer period). The entry date into the analysis will
be the index date (earliest of first diagnosis of depression
or first antidepressant prescription), and the outcome date
will be the earliest of: the date of diagnosis of the outcome
of interest, or the date of death if the outcome was only
recorded on their death certificate. We will use the first
recorded diagnosis of the outcome of interest rather than
recurrent events. Patients who do not have the outcome
of interest within 5 years will be censored at the earliest
of: date of death, date of leaving the practice, date of the
latest download of data, the study end date or 5 years after
the index date. For the analysis of each outcome we
will exclude patients who had already had the outcome
at baseline.
For the main analyses patients will be considered to be
exposed to a drug throughout periods covered by the
duration of the prescriptions if there were no gaps of
more than 90 days between the end of one prescription
and the start of the next prescription to allow for not
having a precise date when the patient finished the
prescription. A prescription after more than 90 days will
count as a new treatment episode. Where there are gaps
of more than 90 days between the end of one prescription
and the start of the next prescription then patients will be
counted as exposed to antidepressant medication for the
first 90 days of the gap and then unexposed until the date
of the next prescription.
The analysis will calculate hazard ratios for current
treatment for each separate class of antidepressants
(SSRIs, TCAs and other antidepressants) compared with
no current treatment. It is anticipated that the number
of patients prescribed MAOIs will be too small for this
group to be analysed, so any patients prescribed MAOIsat any time will be excluded from the analysis. Further
analyses will compare each antidepressant class directly
with SSRIs as the reference category, and will assess
associations with dose of antidepressant according to
each antidepressant class and duration of antidepressant
use treated as a time-varying exposure (categorised for
each class of antidepressant drug as: 1–28 days after the
first prescription in a treatment episode; 29–84 days after
and 85+ days after) and time since stopping (1–28 days,
29 to 84 days and 85 to 182 days after stopping
treatment). Analyses will be carried out for individual
antidepressants where numbers are sufficient. We will
carry out unadjusted and adjusted analysis controlling for
the potential confounding variables listed above.
For the more common outcomes we will carry out
subgroup analyses and tests of interaction to examine
whether associations differ by age, sex and ethnic group.
The assumptions of the Cox proportional hazards model
will be checked graphically.
We will use a P value of < 0.01 (two tailed) to determine
statistical significance since there are multiple outcomes.
We will carry out Wald’s significance tests to determine
whether there are significant differences between the anti-
depressant classes overall, excluding the group with no
current treatment. We will also do this for the analyses of
individual drugs.
As a sensitivity analysis we will repeat the analyses
above restricted to patients who received at least one
prescription for an antidepressant during follow-up,
since the untreated group may differ in a number of ways
which could lead to residual confounding. A further
analysis will include all adverse outcomes that occur
within the entire follow-up period, so associations with
long term use can be examined.
Absolute risks of the adverse events will also be estimated
and presented. We will estimate absolute risks of the
adverse events at 1, 3 and 5 years from the baseline date
according to each antidepressant class and for individual
drugs using a published formula [19].Sample size
All eligible patients on the database will be included in
the study to maximise study power.Self-controlled case series analysis
We will also perform self-controlled case series analyses
using data only on patients who have had adverse events.
This is an internally controlled method whereby analy-
ses are carried out only in patients with the outcome
of interest, which has the advantage of implicitly
adjusting for all measured and unmeasured fixed
confounding variables within patients and so reduces
residual confounding and indication bias [20,21].
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the relative incidence of the outcomes of interest for
defined time periods of risk after the first prescription for
antidepressants compared with an unexposed baseline
period. We will only use the first recorded diagnosis of the
outcome of interest rather than recurrent events. Patients
who have the outcome of interest occurring on the same
day as their first prescription for antidepressants will be
distinguished in the analysis. We will account for multiple
periods of exposure in the analysis, defining a period of
antidepressant treatment as one without gaps of more
than 90 days between the end of a prescription and the
start of the next prescription. A prescription after more
than 90 days will count as a new treatment episode. We
will adjust for age in the analyses.
The time periods for assessing potential short term
effects of antidepressants will be defined for each class of
antidepressant drug as: 0 days (day of first prescription in
each treatment episode); 1–28 days after the first prescrip-
tion; 29–84 days and 85+ days (remaining treatment
period); and periods after stopping treatment (1–28 days,
29 to 84 days and 85 to 182 days after stopping). These risk
periods were selected as they enable examination of short
term and longer term effects of antidepressants on the risks
of adverse events and are the same as those used in our
previous study of antidepressants in older people [13]. The
28 days before the first prescription in each treatment
episode will be considered as a separate category, as an
occurrence of the outcome of interest in this period could
affect the probability of an antidepressant prescription.
Time periods outside these specified risk periods will
contribute to the baseline person time i.e. the unexposed
periods.
The baseline period will be restricted to the year
before the index date (earliest of first diagnosis of
depression or first antidepressant prescription) and up
to 5 years after diagnosis, to reduce the influence of
time varying factors.
Discussion
The findings of this study will help to establish the relative
safety and balance of risks for different antidepressant
drugs in people aged under 65 years, in order to support
decision making for clinicians and patients considering
treatment with antidepressant drugs.
Primary care databases with their large volumes of
high quality data on representative populations over
many years are well suited to the study of unintended
effects of medication.
The current study has a number of strengths. It will
include a large and representative cohort of people with
a recorded diagnosis of depression and will be used to
calculate absolute as well as relative risks of a number of
serious adverse outcomes. The data on patients in thecohort were recorded prospectively, so all information
on prescriptions for antidepressants and potential con-
founding variables was recorded before the occurrence of
an adverse outcome, meaning that results will not be sus-
ceptible to recall bias.
Prescriptions are reliably recorded in primary care
records, and the drugs under consideration in this study
are only available on prescription reducing misclassification
of exposure. We will have detailed information on
prescriptions for antidepressants issued in primary care
throughout the follow-up period, so we will be able to
carry out comprehensive analyses investigating associations
by dose and duration and for individual drugs as well
as for antidepressant class. This contrasts with many
cohort or case–control studies in which information
on antidepressant use is self-reported or collected
only at the start of the study.
The main concern with observational studies of drug
safety such as this one is indication bias which occurs
when patients are prescribed drugs for a condition that is
itself associated with the outcome of interest. To reduce
this bias, we will restrict our study cohort to only include
patients with a recorded diagnosis of depression, so that
all patients had the same indication for treatment. We will
also adjust for a range of potential confounding factors
which would be expected to reduce the effect of this bias
Residual confounding may also affect the findings, as
certain potential confounding variables may not be re-
corded on the database or may not be recorded in
sufficient detail to completely remove their confounding
effect. The self-controlled case series analysis will help to
determine the extent of this, since it is a within patients
comparison, which implicitly removes the effects of all
characteristics that vary between patients, irrespective of
whether or in how much detail they have been recorded on
the database, assuming that they do not vary over time
within the observation period [20,21].
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